AI models need more data about biology, and OpenAI is paying to create it

Last year, the clinical trial policy analyst Ruxandra Teslo posted an idea for super-charging medical AI systems: use data from failed biotech companies. By bidding at their bankruptcy proceedings, she proposed, it might be possible to obtain detailed regulatory filings, manufacturing strategies, and safety data—information usually kept hidden as valuable trade secrets. She called these…

Read it at MIT Technology Review ↗

← Front page